| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.9 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |